Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029

Global Short-acting Recombinant Human Erythropoietin Drugs Supply, Demand and Key Producers, 2023-2029

The global Short-acting Recombinant Human Erythropoietin Drugs market size is expected to reach $ 14300 million by 2029, rising at a market growth of 6.1% CAGR during the forecast period (2023-2029).

The market for short-acting recombinant human erythropoietin drugs is currently in a steady growth phase, with its size gradually expanding, and sales continuing to rise. These drugs find extensive use in the treatment of anemia, especially in patients with chronic kidney disease, cancer chemotherapy recipients, and individuals requiring correction of hemoglobin levels pre-surgery. Future developments may include further expansion into additional clinical applications and more convenient administration routes, along with improved manufacturing techniques to meet the growing healthcare demands.

Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production predominates in the fetal and perinatal period, renal production is predominant during adulthood.

This report studies the global Short-acting Recombinant Human Erythropoietin Drugs production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Short-acting Recombinant Human Erythropoietin Drugs, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Short-acting Recombinant Human Erythropoietin Drugs that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Short-acting Recombinant Human Erythropoietin Drugs total production and demand, 2018-2029, (K Units)

Global Short-acting Recombinant Human Erythropoietin Drugs total production value, 2018-2029, (USD Million)

Global Short-acting Recombinant Human Erythropoietin Drugs production by region & country, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Short-acting Recombinant Human Erythropoietin Drugs consumption by region & country, CAGR, 2018-2029 & (K Units)

U.S. VS China: Short-acting Recombinant Human Erythropoietin Drugs domestic production, consumption, key domestic manufacturers and share

Global Short-acting Recombinant Human Erythropoietin Drugs production by manufacturer, production, price, value and market share 2018-2023, (USD Million) & (K Units)

Global Short-acting Recombinant Human Erythropoietin Drugs production by Type, production, value, CAGR, 2018-2029, (USD Million) & (K Units)

Global Short-acting Recombinant Human Erythropoietin Drugs production by Application production, value, CAGR, 2018-2029, (USD Million) & (K Units).

This reports profiles key players in the global Short-acting Recombinant Human Erythropoietin Drugs market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Amgen, Johnson & Johnson, Roche, Kyowa Kirin, LG Chem, Daewoong Pharmaceutical, Wockhardt, CJ Healthcare and 3SBio, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Short-acting Recombinant Human Erythropoietin Drugs market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.

Global Short-acting Recombinant Human Erythropoietin Drugs Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Short-acting Recombinant Human Erythropoietin Drugs Market, Segmentation by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others

Global Short-acting Recombinant Human Erythropoietin Drugs Market, Segmentation by Application
Anemia
Kidney Disorders
Others

Companies Profiled:
Amgen
Johnson & Johnson
Roche
Kyowa Kirin
LG Chem
Daewoong Pharmaceutical
Wockhardt
CJ Healthcare
3SBio
Kexing Biopharm
Harbin Pharmaceutical Group
Beijing Four Rings Bio-Pharmaceutical

Key Questions Answered

1. How big is the global Short-acting Recombinant Human Erythropoietin Drugs market?

2. What is the demand of the global Short-acting Recombinant Human Erythropoietin Drugs market?

3. What is the year over year growth of the global Short-acting Recombinant Human Erythropoietin Drugs market?

4. What is the production and production value of the global Short-acting Recombinant Human Erythropoietin Drugs market?

5. Who are the key producers in the global Short-acting Recombinant Human Erythropoietin Drugs market?